YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Shares of Pharvaris PHVS have gained 10% over the past month, due to the positive top-line data announced on Sept. 8, 2026, from the pivotal phase III CHAPTER-3 study, which evaluated its lead drug candidate, deucrictibant's extended-relea…
BioCryst Pharmaceuticals' (BCRX) Ordaleyo faces competitive pressure in the hereditary angioedema tr PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
The S&P 500 Index ($SPX) (SPY) closed down -0.58% on Tuesday, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -1.18%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.12%. E-mini S&P futures (ESU26) fell -0.57%, and Septemb…
Biotech stocks Roivant and Pharvaris hit records Tuesday on "blowout" and "bull case" results for lung and swelling disease treatments. Continue Reading
Roivant Sciences (ROIV) shares soared 19% after the company said its Pulmovant unit's phase 2 PHocus PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
The S&P 500 Index ($SPX) (SPY) is down -0.32% today, the Dow Jones Industrial Average ($DOWI) (DIA) is down -1.04%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.04%. E-mini S&P futures (ESU26) are down -0.33%, and September E-mini Nas…
The S&P 500 Index ($SPX) (SPY) is down -0.34% today, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.83%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.19%. E-mini S&P futures (ESU26) are down -0.41%, and September E-mini Nas…
Key Points Interested in Moderna, Inc.? Here are five stocks we like better. Marc Lichtenfeld of the Oxford Club highlights three healthcare plays across different time horizons: Moderna for traders, Pharvaris for the next year, and AbbVie…
Note: the trade details cited in this article come from The Claude Portfolio account on X, a third-party account not affiliated with Anthropic. It tracks how different AI models would trade if given a live portfolio. Claude AI recently add…
Johannes Gerardus Christiaan Petrus Schikan, Director, reported the sale of 37,600 shares of Pharvaris N.V. (NASDAQ:PHVS) in open-market transactions valued at approximately $1.33 million, according to a SEC Form 4 filing. Transaction summ…
Key Points Schikan sold 37,600 shares over June 29, 2026 and June 30, 2026, generating ~ $1.33 million in gross proceeds based on a weighted average price of around $35.41 per share. This transaction represented 10.66% of his direct holdin…
Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedemaExplains the scientific foundation for targeting the bradykinin B2 receptor as a thera…
[Abstract stock market chart with multicolored candlestick patterns and numeric overlays on a dark background. Concept for trading, investing, cryptocurrency markets and digital economy presentations.] vadishzainer/iStock via Getty Images…
(RTTNews) - Biopharmaceutical company Pharvaris N.V. (PHVS) announced Monday that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for deucrictibant immediate-release (IR) capsule (20 mg) for the on-d…
ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-media…
On May 15, 2026, Saturn V Capital Management LP disclosed in an SEC filing that it sold 822,007 shares of Dyne Therapeutics(NASDAQ:DYN), an estimated $14.17 million transaction based on quarterly average pricing. What happened According to…
Key Points Saturn V sold 1,504,880 shares of Ocular Therapeutix in the first quarter; the estimated transaction value was $14.34 million. Meanwhile, the quarter-end position value declined by $18.27 million, reflecting both share sales and…
On May 15, 2026, Saturn V Capital Management disclosed a full exit from Ocular Therapeutix(NASDAQ:OCUL), selling 1,504,880 shares in a trade estimated at $14.34 million based on quarterly average pricing. What happened According to an SEC…
On May 1, 2026, Peng Lu, Chief Medical Officer of Pharvaris N.V.(NASDAQ:PHVS), sold 14,166 common shares for approximately ~$427,000 through a scheduled option exercise and immediate sale, as disclosed in the SEC Form 4 filing. Transaction…
Director Johannes Gerardus Christiaan Petrus Schikan reported the sale of 7,100 shares of Pharvaris N.V.(NASDAQ:PHVS) in two open-market transactions, according to an SEC Form 4 filing. Transaction summary Metric Value Shares sold (direct)…
Shares of KalVista Pharmaceuticals catapulted Wednesday on a $1.9 billion takeover offer from Italy's Chiesi Group. Continue Reading
ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-med…
Key Points CEO Berndt Modig sold 23,333 shares on April 9, 2026, generating a transaction value of ~$647,000 at a weighted average price of around $27.74 per share. The sale represented 2.09% of Modig's total Pharvaris holdings at the time…
On April 9, 2026, Berndt Modig, Chief Executive Officer of Pharvaris N.V.(NASDAQ:PHVS), reported the direct sale of 23,333 common shares for a total transaction value of approximately $647,000, according to a SEC Form 4 filing. Transaction…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Stifel upgraded Texas Instruments (TXN) to…
BioCryst Pharmaceuticals (BCRX) remains undervalued even with a recent price increase due to unconf PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
5AM Venture Management disclosed a full exit from Dianthus Therapeutics(NASDAQ:DNTH) on February 17, 2026, selling 365,053 shares worth $14.36 million in the fourth quarter. What happened According to a Securities and Exchange Commission (…
Key Points 5AM Venture Management sold 365,053 shares of Dianthus Therapeutics in the fourth quarter. The quarter-end position value decreased by $14.36 million as a result of the sale, which marked a full exit from Dianthus. The position…
On February 17, 2026, 5AM Venture Management reported selling its entire stake in Praxis Precision Medicines(NASDAQ:PRAX), an estimated $9.01 million trade based on last-disclosed position values. What happened According to a Securities an…
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. About a dozen biotechnology companies currently stand out as the most likely to receive inter…
Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of RAPIDe-3 endpoints ZUG, Switzerland, March…
Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE attacks ongoing; timeline remains on-t…
Pharvaris N.V. (NASDAQ:PHVS) is one of the best small cap stocks to buy with huge upside potential. Morgan Stanley analyst Maxwell Skor reiterated a Buy rating on Pharvaris N.V. (NASDAQ:PHVS) on December 15, setting a $41 price target. Pha…
Key Points Austin-based Saturn V Capital Management acquired 886,332 shares of Pharvaris in the third quarter. Saturn V now holds 886,332 PHVS shares valued at $22.1 million. PHVS is a new addition, accounting for 4.9% of 13F AUM, which pl…
Key Points Austin-based Saturn V Capital Management acquired 886,332 shares of Pharvaris in the third quarter. Saturn V now holds 886,332 PHVS shares valued at $22.1 million. PHVS is a new addition, accounting for 4.9% of 13F AUM, which pl…
Shares of Pharvaris PHVS rose nearly 22% on Wednesday after the company announced positive results from the phase III RAPIDe-3 study evaluating its lead pipeline drug deucrictibant in the hereditary angioedema (HAE) indication. This study…